Theravance Biopharma, Inc. — Form SCHEDULE 13D/A
Filed September 25, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Weiss Asset Management LP filed an amended Schedule 13D/A regarding Theravance Biopharma, Inc. on September 25, 2026. The filing document does not contain the specific share count, percentage ownership, acquisition details, or dates of transactions—only the header and filing metadata are visible in the provided text.
Why this rating
Schedule 13D amendments are routine filings when ownership positions change. Without disclosed share counts or ownership % details, cannot assess materiality. Standard regulatory disclosure.
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.